Zymeworks Long Term Debt 2016-2022 | ZYME
Zymeworks long term debt from 2016 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Zymeworks Annual Long Term Debt (Millions of US $) |
2021 |
$ |
2020 |
$ |
2019 |
$ |
2018 |
$ |
2017 |
$ |
2016 |
$4 |
2015 |
$ |
Zymeworks Quarterly Long Term Debt (Millions of US $) |
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
2020-03-31 |
|
2019-12-31 |
|
2019-09-30 |
|
2019-06-30 |
|
2019-03-31 |
|
2018-12-31 |
|
2018-09-30 |
|
2018-06-30 |
|
2018-03-31 |
|
2017-12-31 |
|
2017-09-30 |
|
2017-06-30 |
|
2017-03-31 |
$5 |
2016-12-31 |
$4 |
2016-09-30 |
|
2016-06-30 |
|
2016-03-31 |
|
2015-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.570B |
$0.412B |
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|